Categories: All postsAnalysts

Beacon lowers price target on Hydreight Technologies

Beacon Securities analyst Gabriel Leung says Hydreight’s (Hydreight Technologies Stock Quote, Chart, News, Analysts, Financials TSXV:NURS) Q2 results showed strong revenue growth, though margins were below his forecast.

In a Sept. 1 update, Leung maintained his “Speculative Buy” rating on Hydreight but lowered his target to $8.00 from $10.00. His target is based on 15 times his calendar 2027 EV/EBITDA estimate, down from 17 times previously.

Hydreight reported Q2 revenue of $28.0-million, up 421% year-over-year and ahead of Leung’s $27.4-million estimate.

Adjusted EBITDA was $2.9-million, up almost 2,000% year-over-year, but below Leung’s $3.4-million forecast. Adjusted EBITDA margin was 10.3%, compared with his 12.4% estimate.

Leung said growth was driven mainly by the ramp-up of pharmacy sales related to VSDHOne.

Gross margin was 19.4%, below Leung’s 20.8% estimate. Pharmacy gross margin fell to 13.7% from 23.2% a year earlier, reflecting pricing concessions on early deals with new compounding pharmacy partners.

Operating expenses rose to $2.3-million from $1.9-million in Q1, which Leung said still showed positive operating leverage.

Free cash flow was negative $4.2-million, mainly reflecting working capital tied to receivables, prepaid pharmacy purchases and payables.

Leung said Hydreight is using working capital to support compounding pharmacies as they establish new product and treatment lines.

Hydreight ended Q2 with $20-million of cash and $35-million of working capital, which Leung said should support near-term growth. The company also had $11.5-million of convertible debt outstanding.

Hydreight maintained its 2026 guidance for revenue of about $150-million and EBITDA margins of 15% to 17%, though Leung said he continues to model below the margin guidance to be conservative.

The analyst expects Hydreight to generate Adjusted EBITDA of $19.7-million on revenue of $150.6-million in fiscal 2026, improving to Adjusted EBITDA of $29.9-million on revenue of $199.8-million in fiscal 2027.

 

-30-

Tagged with: nurs
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Can you make money with Metatek-Group stock?

Metatek-Group’s (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) strong sequential revenue growth and expectations for a further improvement in… [Read More]

3 hours ago

Ascend Wellness Holdings: Buy, Sell or Hold?

Ascend Wellness Holdings’ (Ascend Wellness Holdings Stock Quote, Chart, News, Analysts, Financials CSE:AAWH.U) return to year-over-year revenue growth and improving… [Read More]

3 hours ago

RBC raises price target on Tidewater Renewables to $31.00

RBC Capital Markets analyst Maurice Choy raised his target on Tidewater Renewables (Tidewater Renewables Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 hours ago

Apotex Health: this analyst just raised his price target

RBC Capital Markets analyst Douglas Miehm raised his target for Apotex Health (Apotex Health Stock Quote, Chart, News, Analysts, Financials… [Read More]

4 hours ago

Magellan Aerospace: Buy, Sell or Hold?

Magellan Aerospace’s (Magellan Aerospace Corp. Stock Quote, Chart, News, Analysts, Financials TSX:MAL) stronger-than-expected third-quarter results and potential opportunities from increased… [Read More]

4 hours ago

Is Cargojet (TSX:CJT) a buy right now?

Cargojet's (Cargojet Stock Quote, Chart, News, Analysts, Financials TSX:CJT) stronger-than-expected third-quarter results and ability to maintain margins despite higher fuel… [Read More]

4 hours ago